Rheumatology

Standard of Care Treatment: Warfarin, Heparin, and DOACs

At a Glance

For Antiphospholipid Syndrome (APS), treatment depends on your symptoms. Warfarin is the standard of care for preventing blood clots, especially in high-risk patients where DOACs are less effective. For pregnancy complications, a combination of low-dose aspirin and Heparin is commonly used.

Treating Antiphospholipid Syndrome (APS) is a balancing act. Because your blood is “primed” to clot, the goal of treatment is to keep your blood flowing smoothly without increasing your risk of bleeding too much. Your treatment plan will depend on whether you have experienced blood clots (thrombosis) or pregnancy complications (obstetric events).

Thrombotic APS: Why Warfarin is Often Key

If you have a history of blood clots, the standard of care is long-term anticoagulation ^[1]. You may wonder why doctors often prescribe Warfarin (a Vitamin K Antagonist) when newer, more convenient blood thinners called DOACs (like rivaroxaban or apixaban) are available.

The answer comes from major clinical trials like TRAPS ^[2]. These studies found that for high-risk APS patients—especially those who are triple-positive or have had an arterial clot like a stroke—DOACs were not as effective as Warfarin at preventing new clots ^[3]^[2].

In some specific cases—such as patients who only have a history of venous clots and are not high-risk—a DOAC may be considered. However, for high-risk APS patients, DOACs are generally avoided ^[4]^[5]. Warfarin remains the “gold standard” for this group, requiring regular blood tests to monitor your INR (International Normalized Ratio) to ensure your dose is correct ^[6]^[7].

Obstetric APS: Protecting Pregnancy

If your APS has primarily affected your pregnancies, the goal is to prevent the antibodies from interfering with the placenta ^[8]. Pre-conception counseling is critical. You should meet with a rheumatologist or high-risk OBGYN before trying to conceive to plan the safest transition to pregnancy-safe medications ^[8]. The standard treatment is a combination of:

Low-Dose Aspirin: To keep the smallest blood vessels open ^[9].
Heparin: Usually given as a daily injection of Low-Molecular-Weight Heparin (LMWH). Heparin does more than just thin the blood; it also helps the placenta attach and protects it from inflammation ^[8]^[10].

With this combination, 70-80% of women with obstetric APS go on to have successful, healthy pregnancies ^[11].

A Simple Treatment Matrix

If Your History Is…	The Standard Treatment Is…	Key Notes
Thrombotic Only	Warfarin (VKA) ^[1]	Lifelong treatment; DOACs usually avoided for high-risk patients ^[12].
Obstetric Only	Aspirin + Heparin ^[8]	Usually taken only during pregnancy and for 6 weeks after ^[11].
Mixed (Both)	Warfarin $\rightarrow$ Heparin	Switch to Heparin before or immediately upon discovering a pregnancy, as Warfarin is unsafe for a developing baby ^[12].

Avoiding the “Second Hit”

Even with medicine, it is vital to avoid triggers that can act as a “second hit” and cause a clot ^[13]:

Hormones: Avoid medications containing estrogen (like some birth control pills or HRT), as estrogen increases clotting risk. Progestin-only options are generally safer ^[14].
Immobility: On long flights or after surgery, your blood moves more slowly. Talk to your doctor about “bridging” or extra protection ^[15].
Infection: Acute illnesses can inflame your system. Ensure you manage infections promptly with your care team ^[15].

For more on daily life, proceed to Living with APS, Survivorship, and Monitoring.

Common questions in this guide

Why is Warfarin preferred over DOACs for Antiphospholipid Syndrome?

Clinical trials have shown that for high-risk APS patients, DOACs are not as effective as Warfarin at preventing new blood clots. Warfarin remains the gold standard treatment for patients with a history of thrombosis, especially those who are triple-positive.

What is the treatment for obstetric Antiphospholipid Syndrome?

To prevent pregnancy complications, the standard treatment combines low-dose aspirin and Heparin. This combination helps keep small blood vessels open, reduces inflammation, and protects the placenta, leading to healthy pregnancies for the majority of women.

Do I need to stop taking Warfarin if I want to get pregnant?

Yes, Warfarin is unsafe for a developing baby. You should consult with a rheumatologist or high-risk OBGYN before trying to conceive so you can safely transition from Warfarin to a pregnancy-safe blood thinner like Heparin.

What triggers should I avoid to prevent a blood clot with APS?

You should avoid triggers that can act as a "second hit" and cause a clot. These include estrogen found in some birth control or hormone replacement therapy, periods of prolonged immobility like long flights, and acute infections.

What is an INR and why does it need to be monitored?

INR stands for International Normalized Ratio, which is a blood test that measures how quickly your blood clots. If you take Warfarin, you need regular tests to check your INR to ensure your medication dose is safely preventing clots without causing excessive bleeding.

Curated prompts to bring to your next appointment.

1.What is my target International Normalized Ratio (INR) range, and how often will I need to be tested?
2.Am I considered 'high-risk' (triple-positive), and is that why you recommend Warfarin over a DOAC?
3.If I plan to become pregnant, at what point do I need to stop taking Warfarin and start Heparin?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (15)

1
Pulmonary Embolism in Antiphospholipid Syndrome (APS)-Where Are We and Where Are We Going?
Lucki M, Grygiel-Górniak B, Lucka E, et al.
International journal of molecular sciences 2026; (27(2)) doi:10.3390/ijms27020895.
PMID: 41596541
2
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V, Denas G, Zoppellaro G, et al.
Blood 2018; (132(13)):1365-1371 doi:10.1182/blood-2018-04-848333.
PMID: 30002145
3
Efficacy and Safety of Direct Oral Anticoagulants in Patients With Antiphospholipid Syndrome: A Systematic Review and Meta-Analysis.
Gullapalli K, Prasad RM, Al-Abcha A, et al.
Cureus 2022; (14(9)):e29449 doi:10.7759/cureus.29449.
PMID: 36299971
4
Direct oral anticoagulants versus Vitamin K antagonists in antiphospholipid syndrome: A systematic review and meta-analysis.
Celia AI, Vescovo GM, Sarto G, et al.
Seminars in arthritis and rheumatism 2025; (73()):152741 doi:10.1016/j.semarthrit.2025.152741.
PMID: 40344935
5
Direct oral anticoagulants versus warfarin in patients with antiphospholipid syndrome: A meta-analysis of randomized controlled trials.
Lee YH, Song GG
Lupus 2022; (31(11)):1335-1343 doi:10.1177/09612033221118463.
PMID: 35968627
6
Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management.
Knight JS, Branch DW, Ortel TL
BMJ (Clinical research ed.) 2023; (380()):e069717 doi:10.1136/bmj-2021-069717.
PMID: 36849186
7
Antiphospholipid Syndrome in Patients with Venous Thromboembolism.
Pengo V, Denas G
Seminars in thrombosis and hemostasis 2023; (49(8)):833-839 doi:10.1055/s-0042-1749590.
PMID: 35728601
8
Preeclampsia and the Antiphospholipid Syndrome.
Mayer-Pickel K, Nanda M, Gajic M, Cervar-Zivkovic M
Biomedicines 2023; (11(8)) doi:10.3390/biomedicines11082298.
PMID: 37626793
9
Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.
Tektonidou MG, Andreoli L, Limper M, et al.
RMD open 2019; (5(1)):e000924 doi:10.1136/rmdopen-2019-000924.
PMID: 31168416
10
Antiphospholipid Syndrome: State of the Art of Clinical Management.
Depietri L, Veropalumbo MR, Leone MC, Ghirarduzzi A
Cardiovascular drugs and therapy 2025; (39(2)):385-404 doi:10.1007/s10557-023-07496-3.
PMID: 37572208
11
Managing antiphospholipid syndrome in pregnancy.
Schreiber K, Hunt BJ
Thrombosis research 2019; (181 Suppl 1()):S41-S46 doi:10.1016/S0049-3848(19)30366-4.
PMID: 31477227
12
Diagnosis and management of antiphospholipid syndrome.
Ahn Y, Hawkins C, Pearson E, Kubler P
Australian prescriber 2024; (47(6)):179-185 doi:10.18773/austprescr.2024.055.
PMID: 39777043
13
Antiphospholipid syndrome in pregnancy: a comprehensive literature review.
Murvai VR, Galiș R, Panaitescu A, et al.
BMC pregnancy and childbirth 2025; (25(1)):337 doi:10.1186/s12884-025-07471-w.
PMID: 40128683
14
Aortic mural thrombosis with bilateral renal infarction in a woman taking dienogest for adenomyosis: A case report and literature review.
Lee KY, Cheng CL, Chiang YC
Taiwanese journal of obstetrics & gynecology 2025; (64(5)):842-846 doi:10.1016/j.tjog.2024.08.015.
PMID: 40935463
15
Precipitating factors of catastrophic antiphospholipid syndrome: the role of anticoagulant treatment in a series of 112 patients.
Stammler R, Nguyen Y, Yelnik C, et al.
Journal of thrombosis and haemostasis : JTH 2023; (21(5)):1258-1265 doi:10.1016/j.jtha.2023.02.007.
PMID: 36792010

This page explains standard treatments for Antiphospholipid Syndrome (APS) for educational purposes. Always consult your rheumatologist, hematologist, or OBGYN before starting, stopping, or changing any blood-thinning medications.

Get notified when new evidence is published on Antiphospholipid syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents